Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study

Laura Pini; Diego Bagnasco; Bianca Beghe; Fulvio Braido; Paolo Cameli; Marco Caminati; Cristiano Caruso; Claudia Crimi; Gabriella Guarnieri; Manuela Latorre; Francesco Menzella; Claudio Micheletto; Andrea Vianello; Dina Visca; Benedetta Bondi; Yehia El Masri; Jordan Giordani; Andrea Mastrototaro; Matteo Maule; Alessandro Pini; Stefano Piras; Martina Zappa; Gianenrico Senna; Antonio Spanevello; Pierluigi Paggiaro; Francesco Blasi; Giorgio Walter Canonica

doi:10.20944/preprints202402.1390.v1

How to cite: Pini, L.; Bagnasco, D.; Beghe, B.; Braido, F.; Cameli, P.; Caminati, M.; Caruso, C.; Crimi, C.; Guarnieri, G.; Latorre, M.; Menzella, F.; Micheletto, C.; Vianello, A.; Visca, D.; Bondi, B.; El Masri, Y.; Giordani, J.; Mastrototaro, A.; Maule, M.; Pini, A.; Piras, S.; Zappa, M.; Senna, G.; Spanevello, A.; Paggiaro, P.; Blasi, F.; Canonica, G.W. Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study. Preprints 2024, 2024021390. https://doi.org/10.20944/preprints202402.1390.v1 Pini, L.; Bagnasco, D.; Beghe, B.; Braido, F.; Cameli, P.; Caminati, M.; Caruso, C.; Crimi, C.; Guarnieri, G.; Latorre, M.; Menzella, F.; Micheletto, C.; Vianello, A.; Visca, D.; Bondi, B.; El Masri, Y.; Giordani, J.; Mastrototaro, A.; Maule, M.; Pini, A.; Piras, S.; Zappa, M.; Senna, G.; Spanevello, A.; Paggiaro, P.; Blasi, F.; Canonica, G.W. Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study. Preprints 2024, 2024021390. https://doi.org/10.20944/preprints202402.1390.v1

Abstract

Background: Severe eosinophilic asthma (SEA) represents a substantial global health burden. Benralizumab has been shown to restore good control of asthma. Robust data on benralizumab effectiveness over periods longer than 2 years are still scarce. Methods: This retrospective multicentric study was conducted on 108 Italian SEA patients treated with benralizumab for up to 36 months. Clinical outcomes were evaluated at 6, 12, 24 and 36 months. Partial and complete clinical remission (CR) were also assessed. Data were analysed either with descriptive statistics or using linear, logistic, and negative binomial mixed-effect regression models. Results: Benralizumab induced a persistent reduction in exacerbation rates (p

Keywords

Subject

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Not displayed online.

Please leave your comment to this article below.

Mathematical equations can be typed in either LaTeX formats \\[ ... \\] or $$ ... $$, or MathML format <math> ... </math>. Try the LaTeX or MathML example.

Type equation:

Preview:

Copy equation into message below

Close menu

Please click a symbol to insert it into the message box below:

Please enter the link here:

Optionally, you can enter text that should appear as linked text:

Copy link into message below

Please enter or paste the URL to the image here (please only use links to jpg/jpeg, png and gif images):

Copy image into message below

Type author name or keywords to filter the list of references in this group (you can add a new citation under Bibliography):

No existing citations in Discussion Group

Wikify editor is a simple editor for wiki-style mark-up. It was written by MDPI for Sciforum in 2014. The rendering of the mark-up is based on Wiky.php with some tweaks. Rendering of mathematical equations is done with MathJax. Please send us a message for support or for reporting bugs.

Please declare any conflicts of interest you may have with this paper, financial or otherwise.

I do not have a conflict of interest

I would like to declare a conflict of interest

Display my name on the website

Captcha

Renew

I accept the following conditions:

Comments must follow the standards of professional discourse and should focus on the scientific content of the article. Insulting or offensive language, personal attacks and off-topic remarks will not be permitted. Comments must be written in English. Preprints reserves the right to remove comments without notice. Readers who post comments are obliged to declare any competing interests, financial or otherwise.

Unlocking the Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Three-Year Real-Life Study

Abstract

Keywords

Subject

Comments (0)